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ABSTRACT
Autophagy is a key biological phenomenon conserved from yeast to mammals. Under basal conditions, activation of autophagy leads 
to the protein degradation as well as damaged organelles for maintaining cellular homeostasis. Deregulation of autophagy has been 
identified as a key mechanism contributing to the pathogenesis and progression of several liver diseases, including hepatocellular car-
cinoma (HCC), one of the most common and mortal types of cancer. Currently used treatment strategies in patients with HCC result in 
variable success rates. Therefore, novel early diagnosis and treatment techniques should be developed. Manipulation of autophagy may 
improve responses of cancer cell to treatments and provide novel targeted therapy options for HCC. In this review, we summarized how 
our understanding of autophagy-cell death connection may have an impact on HCC therapy.
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INTRODUCTION
Autophagy is a catabolic response of cells to stress. During 
this process, cargo is delivered to the lysosomes for deg-
radation, supporting new building block synthesis and al-
lowing cells to maintain homeostasis. Autophagy is active 
at a basal level in cells, and it may further be upregulated 
in response to several types of stresses that disturb cellu-
lar homeostasis, including low cellular ATP levels, nutrient 
and growth factor deprivation, hypoxic conditions, en-
doplasmic reticulum (ER) stress, pathogen entry, or anti-
cancer drug treatment (1). Autophagy products feed into 
cellular energy-generation pathways, facilitating cell sur-
vival under stressful conditions. In contrast, overactiva-
tion of autophagy may indeed lead to cell death through 
so far not well understood mechanisms as an alternative 
nonapoptotic programmed cell death mechanism, “auto-
phagic cell death” has been reported to be responsible for 
killing cells in a number of scenarios (2-4).
Abnormalities related to autophagy are known to be re-
lated to various human pathologies ranging from neuro-
degenerative diseases to cancer, including hepatocellu-
lar carcinoma (HCC) (5). Moreover, autophagy has been 
described as one of the central pathways for liver health 
and disease. In starved animals, a grand majority of total 
protein and glycogen degradation in the liver depends on 
autophagic degradation (6). On the other hand, autophagy 
is related to several liver diseases, including fatty liver dis-
ease and HCC (7,8). For instance, blockage of autophagy 
and autophagolysosomal degradation in mice using genet-
ic tools resulted in hepatosteatosis and hepatomegaly (9).
The role of autophagy in cancer-related processes is 
currently under investigation. Yet, a picture started to 
emerge. A number of studies showed that during transi-
tions from normal cells to cancer cells, autophagy either 
plays a tumor-suppressor role or prevents cancer forma-
tion.
In contrast, exploitation of autophagy to deal with hy-
poxia and energy crisis may allow fast-growing and poor-
ly-vascularized tumors to survive and expand.
Therefore, a comprehensive understanding of autopha-
gy pathways that are operational in HCCs may be most 
rewarding, allowing development of new diagnosis and 
treatment techniques.
In this review, we will briefly introduce the basic auto-
phagic machinery and autophagy-cell death connections 
and summarize implication of autophagy-related cell 
death and survival for HCC management.
Autophagy mechanisms
The basic autophagy mechanism is conserved from yeast 
to man. It is tightly regulated by almost 40 different ATG 
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(Autophagy) genes. Following the initial description of 
the pathway in the yeast, function of ATG genes and 
their products were studied under several physiological 
and pathological conditions.
Autophagosome (or autophagic vesicle) and autolyso-
some formation is a result of well-studied sequential 
stages, including induction, vesicle nucleation, lysosome 
fusion, and degradation. Here we will briefly overview au-
tophagosome formation stages and the role of major pro-
teins involved in the machinery (Figure 1).
Autophagosomal membrane lipids that are contributing 
to de novo autophagosome membrane synthesis appear 
to originate from various pre-existing membrane struc-
tures, such as plasma membrane, ER, or mitochondrial 
membranes (10).
The most important upstream regulators of autopha-
gy are the mammalian target of rapamycin complexes 
(mTORC1 and 2). A central serine/threonine kinase, the 
mTOR kinase, is the essential component of both mTOR 
protein complexes. These protein complexes play key 
roles in the regulation of cellular growth, cell-cycle pro-
gression, cell migration, and protein synthesis as well as 
the coordination of the catabolic autophagy activation 
with the activity of these essential cellular anabolic path-
ways.
When the growth conditions are favorable, mTOR com-
plexes are active and the autophagic machinery is shut 
down. mTORC1 regulates the downstream Atg1/Ulk1 
autophagy-related kinase complex (11). Under nutri-
ent-rich conditions, mTOR phosphorylates ATG13 and 
ULK1/2, and their activity is inversely correlated with 
FIP200 phosphorylation. On the other hand, under nutri-
ent deprivation, mTOR targets are dephosphorylated and 
ATG13 binds to ULK1/2 and FIP200. Then, ULK1/2 phos-
phorylates FIP200 and FIP200-ULK1-ATG13 complex 
(12). Hence, activated Atg1/ULK1 complex regulates the 
activity of a second complex named as class-III phospha-
tidylinositol 3-kinase (PI3K) complex, which contains the 
lipid kinase Vps34. The PI3K complex consists of Vps34, 
Vps15, Atg6, and Atg14 in the yeast. The mammalian 
counterparts of this complex include Beclin 1 (BECN1), 
ATG14L (Barkor), AMBRA1, hVps34, and p150 (13). For-
mation of phosphatidylinositol 3-phosphate (PI3P) mol-
ecules on cellular membranes creates a landing pad for 
the recruitment of other proteins and complexes that are 
required for autophagosome formation (1).
During the autophagosome membrane elongation step, 
two ubiquitination-like conjugation systems, namely 
ATG12-5-16L1 and ATG8 systems, are required. In the 
first conjugation system, ATG12 is conjugated to ATG5 
by the help of ATG7 (E1-like enzyme) and ATG10 (E2-like 
enzyme) proteins. Covalent conjugation of ATG12 to the 
lysine 130 residue (K130) of ATG5 is followed by the ad-
dition of ATG16L protein to the complex. Oligomerization 
of ATG16L proteins results in the formation of an auto-
phagy-related 800-kDa protein complex (11). ATG12-5-
16L1 complexes possess an E3-like enzyme activity that 
is required for the second ubiquitination-like conjugation 
system. The second system involves the conjugation of 
ATG8/LC3 to a lipid molecule, generally to a phosphati-
dylethanolamine (PE). After cleavage of the carboxyl-ter-
minus of LC3 protein by Atg4 cysteine proteases, a gly-
cine residue is exposed. In this form, the LC3 protein is 
called LC3-I, a free cytosolic form of the protein.
Then, LC3-I is conjugated to a PE by the help of ATG7 
and ATG3 E2-like enzymes, resulting in the appearance 
of a membrane-bound autophagic LC3-II form. Of note, 
the LC3-II form is associated with mature autophago-
somes, and it is commonly used as a marker of autopha-
gy, and it represents the number and distribution of auto-
phagosomes during autophagic activity analyses. ATG18/
WIPI proteins are other important players in autophago-
some formation. ATG18/WIPI proteins are WD-repeat 
containing proteins that are able to recognize PI3P at the 
Figure 1. Schematic representation of the autophagosome formation 
stages and major proteins and complexes involved in the process
1: Upstream effectors; 2: ULK complex; 3: PI3K complex; 4: ATG5-12-16 com-
plex; 5: LC3 lipidation
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nascent autophagosome and they regulate autophagic 
activity through recruitment of two ubiquitin-like recruit-
ment systems. In the yeast, ATG2 protein interacts with 
ATG18, this interaction was shown to be important for 
the membrane localization of ATG18 and elongation of 
autophagosome membranes. Studies in mammalian cells 
have also underlined the importance of WIPI proteins for 
autophagy. ATG9, a multi-pass transmembrane protein 
localized to late endosomes and the trans-Golgi network, 
is involved in the transport of membranes to forming 
autophagosomes. After completion and closure of auto-
phagic vesicles, the last stage involves their fusion with 
late endosomes or lysosomes. Several membrane fusion 
events connect these two distinct compartments. and 
RAB proteins, SNAP receptor machinery, and dynein-me-
diated transport of autophagosomes along the microtu-
bules are required for the fusion process to occur. Finally, 
the cargo inside the autophagosome is delivered to the 
lysosomal lumen and degraded by the action of hydrolytic 
enzymes in this compartment.
Initially, autophagy was described as a nonselective deg-
radation pathway (14). However, recent studies showed 
that different autophagy receptors that are capable of 
recognizing specific cargo targets were identified, under-
lining the fact that autophagy may be selective (15,16). 
Autophagy receptors include SQSTM1/p62, NBR1, 
NDP52 (also known as a CALCOCO2), OPTN, and NIX 
(also known as BNIP3L) (17-21). Some of these receptors 
are able to bind and ubiquitinate targets. Moreover, sev-
eral receptors share motifs called LIR (LC3-interacting 
region), allowing bridging between LC3 on the autopha-
gosomes selective autophagy targets.
Because autophagy receptors are also delivered to autol-
ysosomes together with the cargo, their cellular levels are 
generally downregulated following autophagy activation. 
Hence, degradation of autophagy receptors is also anoth-
er commonly used marker of autophagic activity.
Autophagy in hepatocellular carcinoma
The role of autophagy in cancer is complex [see (22) for 
a comprehensive review of the topic]. There is experi-
mental evidence that in early phases of cancer formation, 
autophagy functions as an anticancer pathway, prevent-
ing malignant transformation of normal cells to cancer 
cells. On the other hand, autophagy is involved in various 
stages of cancer progression and metastasis. Especially, 
survival of fast-growing tumors has been correlated with 
their autophagic activity. A large collection of articles im-
plicating autophagy in drug resistance exist as well. Here, 
we will summarize the role of autophagy in the context 
of liver cancer.
Liver cancer formation has been observed in a number 
of autophagy mice models. ATG6/BECN1 (Beclin 1) is a 
key gene in the autophagy pathway. BECN1 deletion is 
observed in 40%-75% human cancers (23,24). Inter-
estingly, a heterozygous deletion of atg6/becn1 in mice 
resulted in increased tumorigenesis in multiple tissues, 
including the liver (23,24). Moreover, becn1 deletion ac-
celerated hepatitis B virus (HBV)-related HCCs, under-
lining the importance of atg6/becn1 gene in liver cancer 
formation (23). Deletion of other autophagy genes, such 
as atg5 and atg7, leads to the formation of benign liv-
er adenomas in mice models (25). In addition, liver-spe-
cific atg7 deletion results in hepatomegaly and hepatic 
failure, underlining the role of autophagy in liver homeo-
stasis, disturbance of which may be the cause of HCC. 
Strikingly, additional p62 deletion in a liver-specific atg7 
deficient background alleviated tumor burden, indicating 
that an important role of autophagy in this context is to 
eliminate cellular protein aggregates in a p62-dependent 
manner (26). Similarly, deletion of autophagy-related 
genes Uvrag enhanced susceptibility to HCC develop-
ment in mice (27,28). Therefore, an important role of 
autophagy-related proteins and the autophagy pathway 
in liver cells is the preservation of liver homeostasis and 
prevention of HCC development (Figure 2).
Cancer-preventing effects of autophagy may be related 
to its role in clearing damaged mitochondria, elimination 
of abnormal and mutant proteins and protein aggregates, 
and specific elimination of proliferation-related proteins 
(5,29). Disturbances in autophagic activity result in higher 
levels of reactive oxygen species (ROS) and increase their 
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Figure 2. Tumor-promoter roles of autophagy in HCC
HCC: hepatocellular carcinoma
susceptibility to DNA damage and genomic instability 
(30,31). First, damaged mitochondria and accumulation 
of protein aggregates boost ROS burden in cells. More-
over, other autophagy-related antioxidant mechanisms 
exist as well. For example, activation of NRF2, a key tran-
scription factor in antioxidant defense, has been found to 
be regulated by autophagy (32). Under normal conditions, 
Keap1, an adaptor protein of Cullin-3 ubiquitin ligase, al-
lows ubiquitination and degradation of NRF2. ROS accu-
mulation results in the oxidation of Keap1 and its disso-
ciation from NRF2, leading to its stabilization and nuclear 
migration. Another mechanism of Keap1 elimination is 
selective autophagy. Competitive binding of the auto-
phagy receptor p62 to Keap1 followed by their selective 
autophagic degradation activates NRF2, triggering an an-
tioxidant transcriptional pathway. p62 accumulation has 
been found to drive liver cancer formation in a number of 
mice models (25,33,34).
In contrast, autophagy is described as an important 
mechanism for cancer progression in established ma-
lignancies (Figure 3). For example, basal autophagy is 
elevated in hypoxic regions of some solid tumor types 
and found to be an essential role for tumor cell survival 
in experimental models (35). Tumor neovascularization 
may not always result in a homogenous vessel network, 
and especially in fast-growing tumors, regions that have 
limited access to nutrients and oxygen exist (36). Thus, 
cancer cells in these regions may be more dependent on 
autophagy than normal-growing cells.
Indeed, autophagy has been shown to promote HCC 
growth in experimental studies (37-39). Autophagy is 
also believed to support the survival of cancer cells and 
contribute to metastasis and chemotherapy resistance.
In summary, although autophagy may act as an antitumor 
pathway preventing early stages of cancer development 
in established tumors, it may protect cancer cells from 
various stress conditions, including starvation, oxidative 
stress, hypoxia, and chemotherapy, and it may contribute 
to the growth and spread of cancerous cells (13,40)
Autophagy and cell death
Autophagy is generally considered as a stress response 
and a cell-survival mechanism. It is frequently observed 
that dying cells exhibit autophagy activation. Wheth-
er this autophagic activity is a failing attempt to rescue 
stressed cells or conversely contributes to cell death is 
a matter of scientific debate. Yet under certain condi-
tions, blockage of autophagy using chemicals or genetic 
tools may rescue cells from death. Moreover, autophagy 
activation is observed in a number of necrotic-like pro-
grammed cell death types, including necroptosis and au-
tosis; however, the contribution of autophagy to these 
novel death pathways has not been thoroughly analyzed 
(41). Nevertheless, several independent articles showed 
the existence of a nonapoptotic cell death type that de-
pended on autophagic activity (2,41-46).
In the context of cancer, autophagic cell death is shown 
to limit clonogenic survival. For example, H-ras, one of 
the most commonly mutated proteins in various can-
cers, is found to increase cellular levels of the autopha-
gy protein Beclin 1 and induce caspase-independent cell 
death with autophagic characteristics (42). In multiple 
myelomas, cleavage of autophagic cell death inducer 
BCLAF1 by caspase-10 is required for cancer cell survival 
(43). In addition, several tumor-suppressor-related and 
cell-death-related proteins, including DAPK, DRP1, ZIP, 
p19ARF, and GBA, triggered autophagic cell death (2,45-
48).
Therefore, although autophagy allows cells to survive 
stressful conditions that cancer cells are facing during 
various stages of cancer, excessive autophagy and auto-
phagic cell death may kill cancer cells and limit their pro-
gression and metastasis.
Autophagy and hepatocellular carcinoma therapy
Hepatocellular carcinoma is one of the most common 
cancer types. It is the third leading cause of cancer deaths 
worldwide (49). History of chronic liver disease and cir-
rhosis is among the factors that predispose patients to 
HCC development. Understanding the molecular mecha-
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Figure 3. Tumor-suppressor roles of autophagy in HCC
HCC: hepatocellular carcinoma
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  Autophagy Autophagy effect 
 Therapeutics status on chemotherapy Tested cell lines Reference
Conventional Oxaliplatin Increase Chemoresistance Huh-7 SMMC-7721 (52)
chemotherapeutics Oxaliplatin Increase Chemoresistance HepG2 (51)
 Adriamycin Increase Chemoresistance HepG2 (56)
 Cisplatin Increase Chemoresistance SMMC-7721 (53) 
    Hep3B  
    HepG2 
 5-FU Increase Chemoresistance SMMC-7721  
    Hep3B  
    HepG2 (53)
 Epirubicin Increase Chemoresistance HA22T/VGH (54)
 Pemetrexed Increase Chemoresistance HepG2 (55)
Small molecules Sorafenib Increase Chemoresistance PLC/PRF/5  
    Hep3B  
    HepG2 (63)
 Sorafenib Increase Chemosensitivity Sk-Hep-1  
    PLC/PRF/5  
    Hep3B HepG2 (65)
 Panobinostat Decrease Chemosensitivity Hep3B  
    HepG2  
    Huh-7 (64)
 Bevacizumab Increase Chemoresistance SMMC-7721  
    Hep3B (68)
 Linifanib Increase Chemoresistance HepG2  
    Bel-7404 (69)
 SC-2001  Increase Chemosensitivity Sk-Hep-1  
    PLC/PRF/5  
    Hep3B  
    HepG2 (73)
 ABT-737 Increase Chemoresistance Huh-7  
    PLC/PRF/5  
    Hep3B  
    HepG2 (70)
 Salinomycin Increase Chemosensitivity HepG2 (71)
Natural products Baicalin Increase Chemosensitivity SMMC-7721 (74)
 Galangin Increase Chemosensitivity HepG2 (75)
 Cannabinoids Increase Chemoresistance HepG2  
    Huh-7 (76)
 Berberine Increase Chemosensitivity SMMC-7721  
    HepG2 (77)
 Allicin Increase Chemosensitivity HepG2  
    Hep3B (78)
 Matrine Increase Chemosensitivity HepG2  
    Bel-7402 (79)
 Glycyrrhetinic acid Increase Chemosensitivity HepG2  
    Hep3B (80)
Table 1. Autophagy modulating therapeutics in HCC
nisms of HCC development and the contribution of auto- phagy deregulation to these mechanisms are among im-
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 SCB Increase Chemosensitivity Hep3B ML-1 (81)
 20(S)-Ginsenoside Rg3  Decrease Chemosensitivity Sk-Hep-1  
    HepG2 (82)
 Arenobufagin Increase Chemoresistance HepG2 (83)
 Bufalin Increase Chemoresistance Huh-7  
    HepG2 LO2 (84)
Noncoding RNAs miR-199a-5p Decrease Chemoresistance Huh-7  
    HepG2  (86)
 miR-375  Decrease Chemoresistance Huh-7  
    Hep3B  (87)
 miR-101  Decrease Chemosensitivity HepG2  
    HepG2  
    Hep3B  
    SNU-182  
    Huh-7  
    PLC/PRF/5  
    HepaRG (90, 91)
 miR-21 Decrease Chemoresistance HepG2  
    Huh-7 (92)
 PTENP1 Increase Chemoresistance Mahlavu (94)
Other therapies NVP-BEZ235  Increase Chemoresistance Hep3B  
    PLC/PRF/5 (97)
 MK-2206 Decrease Chemosensitivity Mahlavu  
    PLC SNU387 
    SNU449  
    SNU475 (98)
 GD0068 Decrease Chemosensitivity HepG2  
    Huh-7 (99)
 OSU-03012  Increase Chemoresistance Huh-7 (101)
 Meloxicam  Increase Chemoresistance HepG2  
    Bel 7402  
    Huh-7  
    SMMC-7721  
    SMMC 7402 (103)
 SAHA Increase Chemoresistance HepG2  
    Hep3B  
    Huh-7 (105)
 Radiotherapy Increase N.D. Sk-Hep-1  (107)
 Radiotherapy Increase Chemoresistance Sk-Hep-1  (108)
 ADI-PEG20  Increase Chemoresistance HepG2  
     SMMC-7721 (109)
 CD133/  Increase Chemoresistance HepG2 LO2  
 Prominin-1   Hep3B  
    Huh-7 (94)
HCC: hepatocellular carcinoma; ND: not determined
Table 1. Autophagy modulating therapeutics in HCC
  Autophagy Autophagy effect 
 Therapeutics status on chemotherapy Tested cell lines Reference
portant challenges of modern medicine. Therefore, in this 
section, we will summarize preclinical and clinical studies 
that focused on autophagy in an HCC treatment context 
(Table 1).
Conventional chemotherapeutics
Chemotherapeutic agents were shown to activate auto-
phagy in a number of cancer types. Oxaliplatin is a plat-
inum-based chemotherapy agent that is widely used in 
the treatment of HCC (50,51). Indeed, oxaliplatin treat-
ment led to autophagic activation in both HCC cells and 
xenografts (52). Inhibition of autophagy under these 
conditions increases the cytotoxicity of oxaliplatin, sug-
gesting that autophagy may be an important player in the 
resistance in HCC to oxaliplatin toxicity (51,52). In anoth-
er study, cisplatin and 5-FU were shown to induce the 
formation of autophagosomes in three different HCC cell 
lines, and attenuation of autophagy enhanced the cispla-
tin and 5-FU-induced cell death under both in vitro and 
in vivo conditions (53). The role of autophagy in chemo-
resistance of HCC to epirubicin has also been investigat-
ed. Combination of progesterone was found to overcome 
autophagy-related chemoresistance and allowed effec-
tive cancer cell elimination (54).
Moreover, Yongxi et al. (55) showed that pemetrexed-in-
duced autophagy in HepG2 HCC cell line blocked apop-
tosis activated by ERK inhibition. On the other hand, an-
other chemotherapeutic agent, adriamycin, was found to 
induce mitochondrial depolarization and autophagy, and 
its combination with curcumin to block autophagy fur-
ther decreased the level of proliferation in comparison 
with adriamycin alone (56).
Targeted small molecules
Sorafenib is an FDA-approved tyrosine kinase inhibitor 
(TKI) used in the treatment of HCC (57). The drug in-
creased overall survival even in patients with advanced 
disease (57,58). Sorafenib induces both apoptosis and 
autophagy in HCC cells. Moreover, studies revealed that 
ER stress may be involved in sorafenib cytotoxicity (59). 
Modulation of proteasomal degradation also influenced 
sorafenib effects on cell fate. Combination with prote-
asome inhibitors significantly increased HCC cell death 
compared with sorafenib alone (60). Inhibition of mTOR 
and accumulation of autophagosomes were reported 
upon sorafenib treatment of HCC cells (61). Concomi-
tantly, combination of sorafenib and chloroquine (CQ, a 
drug that prevents autophagosome maturation) had syn-
ergistic effects on tumor growth suppression (61,62). In 
line with this, sorafenib has been found to kill more cells 
when autophagy is attenuated using CQ or following ge-
netic suppression by a specific siRNA (small interfering 
RNA) against Beclin 1 or ATG5 (63). In another study, pa-
nobinostat, a pan HDAC inhibitor, was found to enhance 
the effect of sorafenib by blocking autophagy (64). More-
over, a derivative of sorafenib, SC-59, that has a more 
potent effect on cancer cell viability than sorafenib, was 
shown to downregulate p-Stat3 levels and induce strong 
autophagy activation in HCC cell lines (65). Besides 
sorafenib, another TKI, nilotinib, stimulated autophagy in 
HCC cells through AMPK phosphorylation and regulation 
of PP2A (66).
Combination with another agent, FTY720 (a potent 
sphingosine-1-phosphate receptor agonist), enhanced 
sorafenib-induced cytotoxicity in HCC cells (67).
Other targeted drugs also have autophagy-activating ef-
fects. For example, targeting vascular endothelial growth 
factor (VEGF) by bevacizumab triggered autophagy. 
Moreover, combinatory inhibition of autophagy together 
with bevacizumab elevated apoptosis levels in HCC cells 
(68). Another inhibitor of VEGF, linifanib, also induced 
autophagy in HCC cells, and similarly, its cytotoxic ef-
fects were further enhanced on autophagy suppression 
(69). Ni et al. provided evidence that resistance to the 
bcl-2 inhibitor ABT-737 is a result of the activation of a 
ROS-JNK-autophagy pathway in HCC cells (70). More-
over, salinomycin-mediated suppression of autophagy in 
HCC cells has been reported to result in their cell death 
through defective mitochondria accumulation and ROS 
accumulation (71). In another study, inhibition of Hsp90 
by 17-AAG was shown to sensitize HCC cells against gos-
sypol induced apoptosis through suppression of cytopro-
tective autophagy (72).
In contrast with these findings, a study by Tai et al. 
showed that sorafenib enhanced autophagy-dependent 
cell death in HCC both in vitro and in vivo (65). In line 
with this, SC-2001, an analog of the bcl-2 inhibitor oba-
toclax, induced autophagic cell death in HCC cells (73). 
It is possible that autophagy levels in these set-ups were 
more robust than those in other cited studies, convert-
ing chemoprotective autophagy to a cell death-inducing 
pathway.
Natural products
A number of natural products have been shown to have 
autophagy-related effects on the growth and survival of 
HCC cells. For example, baicalin is a natural flavonoid ob-
tained from the Chinese herb Scutellaria baicalensis, and 
XX
Akkoç and Gözüaçık.  Autophagy in HCC Turk J  Gastroenterol  2018;  29:  xx
XX
Turk J  Gastroenterol  2018;  29:  xx Akkoç and Gözüaçık.  Autophagy in HCC
it exerts an apoptosis and autophagy-dependent inhibi-
tory effect on HCC (74). Alpinia officinarum-derived Ga-
langin is another natural flavonoid that induces autopha-
gy in HCC cells through the activation of TGFb receptor/
Smad axis (75).
Various cannabinoid derivatives showed antitumor ef-
fects against HCC that depend on intact autophagic 
activity. Blockage of autophagy attenuates antitumor 
effects, thus supporting the idea that autophagic cell 
death is active under these circumstances (76). Simi-
larly, berberine, allicin, matrine, and glycyrrhetinic acid 
are plant-derived molecules that show their antitumor 
effects through induction of either apoptosis and/or au-
tophagy in HCC cells (77-80). In another study, admin-
istration of soybean fermentation products containing 
live bacteria (SCB) was shown to suppress HBV-related 
HCC tumor growth; under these conditions, SCB induced 
both apoptosis and autophagy (81). On the other hand, 
steroidal saponin 20(S)-Ginsenoside Rg3 has been shown 
to block autophagy and promotes doxorubicin sensitivity 
in HCC cells and tumors (82).
In addition to plant-derived natural products, venoms 
are another group of natural products that have been 
evaluated for cancer treatment. Arenobufagin, a venom 
isolated from toads, shows significant antineoplastic ef-
ficacy against both naive HepG2 cells and their multidrug 
resistant clones. Inhibition of autophagy is reported to 
enhance the level of apoptosis in this context (83). An-
other toad venom, bufalin, also has an antitumor activity 
on HCC cells, and its efficacy has been found to increase 
under autophagy-attenuated conditions (84).
Noncoding RNAs
MicroRNAs are associated with various cellular phenom-
ena including cell death, differentiation, and diseases. 
Dysregulation of miRNAs is linked to cellular abnormal-
ities and carcinogenesis, and changes in microRNA lev-
els affect tumor growth and progression. As explained in 
detail above, autophagy abnormalities are also associated 
with cancer. Therefore, changes in the levels of a subset 
of miRNAs that control the autophagic activity may have 
important outcomes on cancer cell survival and drug re-
sponses (85).
For example, levels of drug resistance-associated miR-
199a-5p were found to be significantly decreased in 
patients with HCC following treatment with cisplatin. 
In fact, miR-199a-5p has been shown to be responsible 
from the attenuation of cisplatin-induced autophagy in 
HCC cell lines through ATG7 targeting. Inhibition of au-
tophagy in HCC cells blocked miR-199a-5p downregu-
lation-induced cell proliferation and cisplatin resistance 
(86). Another ATG7 targeting miRNA, miR-375, has been 
found to be downregulated in HCCs and decreases HCC 
cell viability under hypoxic conditions (87,88). Another 
miRNA, miR-224, is one of the most studied miRNAs in 
HCC, and it has been shown to target Smad4. Striking-
ly, high miR-224 levels were associated with lower Atg5 
levels as well as lower Smad4 levels, and these findings 
significantly correlated with HBV infection and poor over-
all survival in patients with HCC (89). Interestingly under 
these conditions, autophagy was shown to limit miR-
224 levels through the direct degradation of the miRNA, 
hence resulting in liver tumor suppression (89). MiR-101 
has been characterized as an autophagy-inhibitory miR-
NA, and this effect has been shown to sensitize HCC cells 
against cisplatin, doxorubicin, and 5-FU (90,91). MiR-
NAs were also involved in sorafenib resistance in HCC. 
For instance, Mir-21 is found to suppress autophagy 
via PTEN/Akt axis and lead to sorafenib resistance (92). 
Sorafenib-induced miRNAs were also used for determin-
ing prognosis and follow-up. In a study, miR-423-5p was 
described as a positive regulator of autophagy in HCC 
cells. Levels of this miRNA in patient sera months after 
sorafenib treatment indicated a response to treatment, 
indicating the prognostic value of an autophagy-related 
miRNA in HCC (93).
Long noncoding RNAs (lncRNAs) have been associated 
with HCC as well. For example, PTENP1 is identified in a 
screen of lncRNAs targeting PTEN. In fact, PTENP1 act-
ed as a competitor of several autophagy-regulating miR-
NAs, such as miR-17, miR-19b, and miR-20a, which tar-
get PTEN and PHLPP as well as autophagy genes ULK1, 
ATG7, and p62.
Injection of a PTENP1-expressing virus to mice has been 
shown to stimulate autophagy and attenuated HCC tu-
mor growth (94).
Other approaches
Recent studies indicate that autophagy regulator mTOR 
signaling is upregulated in a significant proportion of 
HCCs (95). Thus, mTOR pathway may be exploited as a 
drug target in HCC. For instance, RAD001 and BEZ235 
are characterized as PI3K/mTOR-inhibitor drugs. Combi-
nation of these two drugs has been shown to suppress 
HCC growth both in vitro cell culture and in vivo in mice 
experiments (96). Moreover, orally available BEZ235 in a 
combination with autophagy blockage is also more ef-
fective in HCC treatment (97). Another molecule, the 
Akt inhibitor MK-2206, has been found to trigger cell 
death, and suppression of autophagy under these exper-
imental conditions has been shown to further enhance 
the efficacy of the inhibitor in HCC cells (98). Another 
Akt inhibitor called GD0068 has shown synergistic ef-
fects with sorafenib and even suppresses the growth of 
sorafenib-resistant HCC cells converting cytoprotective 
autophagy to autophagic cell death (99).
Some studies on nonsteroidal anti-inflammatory drugs 
(NSAIDs) revealed that inhibition of COX-2, which may be 
highly expressed in some tumor types, is the underlying 
mechanism for the cancer-preventive effects attributed 
to these drugs (100). One of the derivatives of the NSAID 
celecoxib, OSU-03012, has been found to exert antitu-
mor activities. Gao et al. revealed that autophagy levels 
were elevated in HCC cells upon OSU-03012 treatment. 
Blockage of autophagy decreased OSU-03012-induced 
cell death under both in vitro and in vivo conditions indi-
cating that autophagic cell death is important in the ef-
fects of the drug in HCC cells (101). Yet in another study, 
suppression of autophagy by 3-MA was found to promote 
NSAID meloxicam-induced apoptosis in HCC (102,103).
Histone acetylation has been linked to cancer through 
aberrant regulation of cancer-related genes. Interest-
ingly, HDAC1 has been reported to be overexpressed 
in HCC; yet, HDAC6 has been found to be decreased in 
HCCs compared with adjacent control tissues, and this 
observation is associated with poor prognosis (104). 
Nevertheless, HDAC inhibitors are tested as promising 
drugs against cancer, and several members of this group 
of drugs were also found to induce autophagy and even 
autophagic cell death in some contexts. SAHA, an im-
portant HDAC inhibitor, has been shown to induce au-
tophagic cell death in HCC cells (105). In another study, 
HDAC1 inactivation inhibited proliferation of tumor cells 
and activate caspase-independent autophagic cell death 
(106). On the other hand, HDAC inhibitors OSU-HDAC42 
and SAHA were both found to induce autophagy in HCC 
cells. Moreover, inhibition of autophagy decreases SA-
HA-induced cell death indicative of autophagic cell death 
activation in HCC (105).
In another study, irradiation was shown to kill HCC cells, 
which was further enhanced by the combination of oxal-
iplatin. In addition to this, when apoptosis was attenuated 
by a PARP inhibitor combination treatment, autophagic 
activation was observed and cell death responses were 
more robust (107). In a follow-up study, the same group 
showed that when HCC cells were treated with high LET 
irradiation, cells died in an autophagy-dependent man-
ner under both in vitro and in vivo conditions (108). In an 
additional study, mTOR-inhibitor RAD001 was found to 
enhance high LET radiation-induced cytotoxicity in HCC 
cells (109). Altogether, high LET radiation-drug combina-
tions have therapeutic effects against HCC, and autoph-
agy appears to take part in the mechanism of action of 
these combinations.
Argininosuccinate synthetase (ASS) has been reported to 
be low in HCC cells. Thus, at least some HCC tumors may 
be auxotrophic for arginine and require arginine supply 
from extracellular sources (110). Consequently, autoph-
agy and cell death were activated in HCC cells when they 
were exposed to a modified form of the arginine-degrad-
ing enzyme arginine deaminase (ADI-PEG20) (111).
Moreover, an arginine-modifying enzyme, the enzyme 
peptidylarginine deiminase IV, has been reported to be 
related to chemoresistance in HCC through regulation of 
autophagy (112).
CONCLUSION
The above-cited studies underline the importance of au-
tophagy for health and disease in the liver. In particular, 
with the advance of studies on autophagy cancer, the 
role of autophagy in HCC development and management 
becomes clearer. Especially, studies on the contribution 
of autophagy and related mechanisms to HCC chemore-
sistance are of special interest. There are several studies 
correlating autophagic activity with resistance to che-
motherapeutic agents, including sorafenib. Several inde-
pendent labs are currently working on finding novel small 
molecules that will be capable of manipulating autophagy 
for treatment purposes. Further studies, including clini-
cal studies, are required to fully reveal the potential of 
the abovementioned strategies and these potential new 
drugs, alone or in combination with classical drugs, for the 
treatment of liver diseases and HCC.
Moreover, a strong connection between autophagy and 
liver pathologies, including nonalcoholic steatohepatitis, 
HBV, and hepatitis C virus infection and cirrhosis, has 
been reported (113). For instance, autophagy constitutes 
a major clearance of mechanism for intracellular patho-
gens, such as viruses. However, some viruses, including 
HBV and HCC, may hijack autophagic membranes during 
their replication (114). In addition, several autophagy de-
ficient animal models have been shown to suffer from 
hepatic steatosis, and independent studies have consis-
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tently demonstrated that autophagy is involved in lip-
id and glycogen metabolism. Evidently, these and other 
abnormalities of liver function and pathologies are also 
closely related to HCC development. Thus, a better un-
derstanding of mechanisms underlying autophagy, its 
abnormalities, and its connection with liver diseases and 
disease-causing factors will certainly improve current di-
agnosis, treatment, follow-up, and prevention strategies 
for HCC.
Autophagy constitutes one of the important medical 
fields that already started to provide examples of bench-
to-bedside transitions. Hence, following this novel but 
fast-growing field will be most rewarding for both basic 
scientists and clinical researchers and practitioners.
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